The double-edged sword of (re)expression of genes by hypomethylating agents: from viral mimicry to exploitation as priming agents for targeted immune checkpoint modulation

Hypomethylating agents (HMAs) have been widely used over the last decade, approved for use in myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML). The proposed central mechanism of action of HMAs, is the reversal of aberrant methylation in tumor ce...

Descripción completa

Detalles Bibliográficos
Autores principales: Wolff, Florian, Leisch, Michael, Greil, Richard, Risch, Angela, Pleyer, Lisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5374693/
https://www.ncbi.nlm.nih.gov/pubmed/28359286
http://dx.doi.org/10.1186/s12964-017-0168-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5374693/
https://www.ncbi.nlm.nih.gov/pubmed/28359286
http://dx.doi.org/10.1186/s12964-017-0168-z

Ejemplares similares